经皮深静脉动脉化治疗无选择重症肢体缺血的初步研究中远期结果
该初步研究纳入7例无传统血运重建选择的重症肢体缺血患者,评估经皮深静脉动脉化(PDVA)的安全性。30天内主要安全终点达标率100%,技术成功率100%;6个月和12个月分别有4例和5例伤口完全愈合,12个月保肢率71%。PDVA安全可行,早期临床结果有前景。
要点
- PDVA技术成功率100%,30天主要安全终点达标率100%。
- 术后TcPO2中位数从8 mmHg升至61 mmHg(p=0.046)。
- 12个月保肢率71%,6个月和12个月伤口完全愈合分别为4/7和5/7。
核心结论
- PDVA是治疗无选择重症肢体缺血的新方法,可能避免大截肢,安全可行且早期结果有前景。
研究设计与样本
- 初步研究纳入7例无传统腔内或外科血运重建选择的重症肢体缺血患者(中位年龄85岁,5例女性)。
- 所有患者为糖尿病,4例为Rutherford 6级缺血,6例基于WIfI分类为高截肢风险。
- 主要安全终点为30天内主要不良肢体事件和主要不良冠脉事件,以及6个月内严重不良事件。
主要发现
- 30天内无死亡、膝上截肢或主要再干预,主要安全终点达标率100%。
- 30天内发生2例心肌梗死,临床后果轻微。
- 所有患者症状改善,表现为肉芽组织形成和/或静息痛缓解。
- 6个月和12个月伤口完全愈合分别为4/7和5/7,中位愈合时间4.6个月(95%CI 84-192)。
- 术后TcPO2中位数61 mmHg,术前8 mmHg(p=0.046);伤口愈合时4/5患者TcPO2>40 mmHg。
关键数值与推荐
- 30天主要安全终点达标率100%,技术成功率100%。
- 术后TcPO2中位数61 mmHg vs 术前8 mmHg(p=0.046)。
- 12个月保肢率71%。
- 2例大截肢:1例PDVA血栓形成后膝上截肢,1例感染后膝下截肢。
- 3例分别于6、7、8个月死于与操作或研究器械无关的原因。
临床怎么用
- 对于无传统血运重建选择的重症肢体缺血患者,PDVA可作为避免大截肢的替代选择。
- 术后需监测TcPO2及伤口愈合情况,并关注心血管事件。
局限性
- 样本量小(7例),为初步研究,结果需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the initial clinical experience with percutaneous deep vein arterialization (PDVA) to treat critical limb ischemia (CLI) via the creation of an arteriovenous fistula. METHODS: Seven patients (median age 85 years; 5 women) with CLI and no traditional endovascular or surgical revascularization options (no-option CLI) were recruited in a pilot study to determine the safety of PDVA. All patients were diabetic; 4 had Rutherford category 6 ischemia. Six were classified at high risk of amputation based on the Society for Vascular Surgery WIfI (wound, ischemia, and foot infection) classification. The primary safety endpoints were major adverse limb events and major adverse coronary events through 30 days and serious adverse events through 6 months. Secondary objectives included clinical efficacy based on outcome measures including thermal measurement, transcutaneous partial pressure of oxygen (TcPO2), clinical improvement at 6 months, and wound healing. RESULTS: The primary safety endpoints were achieved in 100% of patients, with no deaths, above-the-ankle amputations, or major reinterventions at 30 days. The technical success rate was 100%. Two myocardial infarctions occurred within 30 days, each with minor clinical consequences. All patients demonstrated symptomatic improvement with formation of granulation tissue, resolution of rest pain, or both. Complete wound healing was achieved in 4 of 7 patients and 5 of 7 patients at 6 and 12 months, respectively, with a median healing time of 4.6 months (95% confidence interval 84-192). Median postprocedure peak TcPO2 was 61 mm Hg compared to a preprocedure level of 8 mm Hg (p=0.046). At the time of wound healing, 4 of 5 of patients achieved TcPO2 levels of >40 mm Hg. There were 2 major amputations, 1 above the knee after PDVA thrombosis and 1 below the knee for infection. Three patients died of causes unrelated to the procedure or study device at 6, 7, and 8 months, respectively. Limb salvage was 71% at 12 months. CONCLUSION: PDVA is an innovative approach for treating no-option CLI and represents an alternative option for the "desert foot," potentially avoiding major amputation. Our results demonstrate its safety and feasibility, with promising early clinical results in this small cohort.
引用
- Kum S, Tan YK, Schreve MA, et al. Midterm Outcomes From a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option Critical Limb Ischemia. J Endovasc Ther. 2017. PMID: 28697694. doi:10.1177/1526602817719283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。